TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A Being Patient report explains four leading theories of Alzheimer’s disease: amyloid buildup, tau tangles, inflammation and immune-system dysfunction, and problems with blood flow or metabolism. The theories overlap, and researchers have not established one complete explanation for what starts the disease or causes neurons to die.
Alzheimer’s disease has no single established cause, and researchers are studying four leading explanations for how it damages the brain: amyloid plaques, tau tangles, inflammation and immune dysfunction, and disrupted blood flow or metabolism. A Being Patient report explains how each theory accounts for part of the disease, while emphasizing that the mechanisms may interact and that the full sequence remains uncertain.
The theories address how brain cells, or neurons, become damaged and lose their connections. Alzheimer’s is progressive: as neurons and synapses are lost, communication across brain networks breaks down. Memory loss is common, in part because early damage often affects the hippocampus, a region involved in forming new memories; disease progression can also affect language, judgment and behavior.
The amyloid hypothesis, a major influence on drug research for more than three decades, holds that beta-amyloid fragments accumulate outside neurons and form plaques. Researchers have proposed that this buildup may trigger further damage, including tau changes, years before symptoms begin. The report says FDA-approved drugs lecanemab and donanemab modestly slowed cognitive decline in clinical trials among people in early Alzheimer’s stages; they are not cures and carry risks, including brain swelling and bleeding, requiring monitoring.
The tau theory focuses on a protein inside neurons. Tau normally helps stabilize internal structures that support the cell. In Alzheimer’s, tau can become abnormal and form tangles, disrupting that support system. The report also describes inflammation and immune responses, including the brain’s microglia, as a possible contributor to injury; a fourth line of research examines vascular and metabolic factors that may affect the brain’s ability to receive oxygen and energy. These are proposed explanations, not settled, independent causes.
How the Theories Shape Treatment
The debate matters because each explanation points researchers toward different ways to detect or treat Alzheimer’s. Amyloid has already shaped diagnostic testing and medicines: the report says plaques can be assessed using PET scans and spinal-fluid tests, and the FDA cleared a blood test in May 2025 to aid identification of amyloid pathology linked to the disease.
Yet clearing a biological marker does not necessarily restore lost function. The report notes that Aduhelm reduced plaques but did not show convincing clinical benefit; its maker discontinued the drug in 2024. Results from lecanemab and donanemab offer evidence of modest slowing, not a cure. Other theories may guide future research, but they do not yet establish a proven alternative explanation or treatment. For patients and families, the distinction is important: a biomarker, a proposed mechanism and a meaningful improvement in symptoms are not the same thing.
Products Worth Considering
iRobot Roomba Max 715 Pet Robot Vacuum with AutoEmpty Dock
eufy Security eufyCam C37 4-Camera Kit with 360° Pan and Tilt
Levoit Vital 100S-P Air Purifier
As an affiliate, we earn on qualifying purchases.
From Plaques to Competing Explanations
In 1906, German psychiatrist Alois Alzheimer described plaques and twisted fibers in the brain of Auguste Deter, a former patient who had experienced worsening memory loss and confusion. Those findings were later identified as amyloid plaques and tau tangles, the characteristic changes that helped define the disease. Their presence, however, has not resolved what initiates Alzheimer’s or how the different forms of brain damage relate.
The amyloid account became a dominant framework and drove much of drug development. Its influence has grown alongside research into other processes, including tau, immune activity and vascular health. The Being Patient report places these ideas side by side rather than presenting one as a definitive answer. It also cites an estimate of 7.4 million Americans age 65 and older living with Alzheimer’s dementia, from the Alzheimer’s Association’s 2026 Facts and Figures report.
“Both γ-secretase and β-secretase inhibitors, which strongly inhibit amyloid-beta production, worsen cognitive and clinical performance in early and late stages of Alzheimer’s disease.”
— Bruno Imbimbo, a researcher at Chiesi Farmaceutici, speaking to Being Patient
What Starts the Brain Damage?
No one theory explains the entire disease, and the report does not establish which process comes first or whether the mechanisms cause one another. Amyloid may contribute to later damage, but debate continues over its role; tau, immune activity, blood flow and metabolism may also interact. The available evidence does not show that any one factor alone accounts for every case.
Treatment results also leave open how much changing a marker affects a person’s daily functioning over time. The reported clinical benefit from approved anti-amyloid drugs is modest, and treatment carries risks that require medical monitoring. Alzheimer’s risk, progression and response to treatment can vary; the report does not provide a way to predict an individual’s course from these theories.
Research Across Multiple Pathways
Researchers are continuing to test treatments aimed at amyloid and other proposed mechanisms, while studying how biomarkers can help identify disease. Further clinical evidence will be needed to clarify which patients may benefit, how durable any slowing of decline is, and how treatment risks compare with potential benefits. Blood-based tests and other diagnostic tools also require evaluation in clinical use.
For now, the four theories remain research frameworks rather than a settled explanation. People considering testing or treatment should discuss the evidence, risks and personal circumstances with a qualified health professional.
Key Questions
What are the four leading theories about Alzheimer’s?
The report describes amyloid buildup, tau tangles, inflammation and immune dysfunction, and vascular or metabolic problems as leading explanations. They may overlap, and none alone is established as the full cause.
Does amyloid cause Alzheimer’s?
Amyloid plaques are a defining feature and a major focus of research, but their precise role remains debated. The report says amyloid-targeting drugs have shown mixed results, with newer approved medicines modestly slowing decline in trials among people in early stages.
Are Alzheimer’s treatments a cure?
No. The report says lecanemab and donanemab modestly slowed cognitive decline in clinical trials; they are not cures and have risks that require regular monitoring.
Can a blood test diagnose Alzheimer’s?
The report says the FDA cleared a blood test in May 2025 to aid in identifying amyloid pathology linked to Alzheimer’s. That is not the same as a test that independently explains the cause of someone’s symptoms; diagnostic decisions should be made with a qualified clinician.
Source: rss
